{"filing":{"accession_number":"0001493152-26-025336","cik":"0001828673","ticker":"HCWB","company_name":"HCW Biologics Inc.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226025336/form8-k.htm"},"events":[{"id":8827,"run_id":7749,"accession_number":"0001493152-26-025336","anchor_item_number":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The filing discloses termination of an exclusive worldwide license agreement with Wugen Inc. for ex vivo rights to HCW9201 and HCW9206 molecules, exercised pursuant to a suspension letter agreement dated May 30, 2025. This represents a material change in the Company's intellectual property licensing arrangements and strategic partnerships, affecting the Company's ability to develop and commercialize key assets.","company_name":"HCW Biologics Inc.","ticker":"HCWB","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":2033,"accession_number":"0001493152-26-025336","item_number":null,"item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses termination of an exclusive worldwide license agreement with Wugen Inc. for ex vivo rights to HCW9201 and HCW9206 molecules, exercised pursuant to a suspension letter agreement dated May 30, 2025. This represents a material change in the Company's intellectual property licensing arrangements and strategic partnerships, affecting the Company's ability to develop and commercialize key assets.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:37:34.162681+00:00","company_name":"HCW Biologics Inc.","ticker":"HCWB","filing_date":"2026-05-27"}]}